Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM901ZW)

Drug Name
Naptumomab estafenatox Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2/3 [1]
Cross-matching ID
TTD Drug ID
DM901ZW

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Oncotrophoblast glycoprotein 5T4 (TPBG) TT70MLA TPBG_HUMAN Immunomodulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Oncotrophoblast glycoprotein 5T4 (TPBG) DTT TPBG 5.278 7.52 7.518 7.012
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Oncotrophoblast glycoprotein 5T4 (TPBG) DTT TPBG 1.30E-01 0.15 0.17
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00420888) ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma. U.S. National Institutes of Health.
2 Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep. 2014 Feb;16(2):370.